Dotmatics said this week that AstraZeneca's Neuroscience Innovative Medicines Unit has selected its platform to manage research data associated with its collaborative drug discovery efforts.
Dotmatics platform will provide a single point of access to all data and functions for AstraZeneca and its partners, the company said. These users will have access to compound registration and tracking tools, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology electronic laboratory notebook and project management capabilities.
The financial details of the agreement were not disclosed.